Bio Roundup: Cholesterol Check, J&J’s Opioid Hit, AbbVie’s Flop & More
Xconomy
AUGUST 30, 2019
But in Paris, this cardiologist will be in a conference center, walking an audience through a slide deck packed with Phase 3 data for a new cholesterol-lowering drug, inclisiran. You might be camping, barbecuing, or sleeping on Monday. It’s Labor Day, after all. Inclisiran’s owner, the Medicines Co.,
Let's personalize your content